Teva Pharmaceutical Industries Limited vs Abbvie Inc.
TEVA vs ABBV — side-by-side comparison from reported financials. TEVA leads 4, ABBV leads 7 of 11 comparable metrics.
Teva Pharmaceutical Industries Limited
TEVA · Healthcare
$41.21+4.99%Strained
Abbvie Inc.
ABBV · Healthcare
$276.43+1.47%Mixed
| Metric | TEVA | ABBV |
|---|---|---|
| Price | $41.21 | $276.43 |
| Market cap | $48.1B | $488B |
| Revenue (TTM) | $17.3B | $64.4B |
| Revenue growth | +5.0% | +1.8% |
| Net margin | 4.1% | 9.8% |
| Free cash flow | $1.35B | $18.2B |
| Net cash (debt) | $1.74B | ($56.2B) |
| 1-year price return | +105.6% | +19.8% |
| P/E | 63.2 | 77.4 |
| P/E vs own history (cheap-side %) | 0% | 23% |
| Dividend yield | — | 2.45% |
| Return on equity | 9% | 96% |
| Altman Z-score | 0.63 | 2.33 |
| CV checks passed | 7 of 10 | 9 of 10 |
| Employees | 32,842 | 57,000 |
Full résumé-style profiles: TEVA CV · ABBV CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.